PharmAthene, Inc. - Product Pipeline Review - Q1 2011

Global Markets Direct, April 2011, Pages: 38

PharmAthene, Inc. – Product Pipeline Review – Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “PharmAthene, Inc. - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- PharmAthene, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of PharmAthene, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of PharmAthene, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the PharmAthene, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate PharmAthene, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of PharmAthene, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the PharmAthene, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with PharmAthene, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of PharmAthene, Inc. and identify potential opportunities in those areas.

List of Tables
List of Figures
PharmAthene, Inc. Snapshot
PharmAthene, Inc. Overview
Key Information
Key Facts
PharmAthene, Inc. – Research and Development Overview
Key Therapeutic Areas
PharmAthene, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
PharmAthene, Inc. – Pipeline Products Glance
PharmAthene, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
PharmAthene, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
PharmAthene, Inc. – Drug Profiles
SparVax
Product Description
Mechanism of Action
R&D Progress
Ciprofloxacin + Valortim
Product Description
Mechanism of Action
R&D Progress
Protexia
Product Description
Mechanism of Action
R&D Progress
Valortim
Product Description
Mechanism of Action
R&D Progress
Valortim + Doxycycline
Product Description
Mechanism of Action
R&D Progress
Protexia
Product Description
Mechanism of Action
R&D Progress
PharmAthene, Inc. – Pipeline Analysis
PharmAthene, Inc. – Pipeline Products by Therapeutic Class
PharmAthene, Inc. - Pipeline Products By Target
PharmAthene, Inc. – Pipeline Products by Route of Administration
PharmAthene, Inc. – Pipeline Products by Molecule Type
PharmAthene, Inc. – Recent Pipeline Updates
PharmAthene, Inc. - Dormant Projects
PharmAthene, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
RypVax
PharmAthene, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Financial Deals Landscape
PharmAthene, Inc., Deals Volume Summary, 2004 to YTD 2011
PharmAthene, Inc., Deals Summary By Region, 2004 to YTD 2011
PharmAthene, Inc., Deals Summary, 2004 to YTD 2011
PharmAthene, Inc. Detailed Deal Summary
Equity Offering
PharmAthene Completes Public Offering Of $5.5 Million
Debt Offering
PharmAthene Completes Private Placement Of $19.3 Million
GTC Biotherapeutics Enters Into An Agreement With Pharmathene
Medarex Enters Into Co-Development Agreement With PharmAthene
Licensing Agreements
GTC Biotherapeutics Extends Licensing Agreement With PharmAthene
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
PharmAthene, Inc. – Pipeline by Therapy Area and Indication, 2011
PharmAthene, Inc. – Pipeline by Stage of Development, 2011
PharmAthene, Inc. – Monotherapy Products in Pipeline, 2011
PharmAthene, Inc. – Combination Treatment Modalities in Pipeline, 2011
PharmAthene, Inc. - Phase II, 2011
PharmAthene, Inc. - Phase I, 2011
PharmAthene, Inc. - Pipeline By Therapeutic Class, 2011
PharmAthene, Inc. - Pipeline By Target, 2011
PharmAthene, Inc. – Pipeline By Route of Administration, 2011
PharmAthene, Inc. – Pipeline By Molecule Type, 2011
PharmAthene, Inc. – Recent Pipeline Updates, 2011
PharmAthene, Inc. - Dormant Developmental Projects, 2010
PharmAthene, Inc. - Discontinued Pipeline Products, 2010
PharmAthene, Inc., Subsidiaries
PharmAthene, Inc., Deals Summary, 2004 to YTD 2011
PharmAthene, Inc., Deals Summary by Region, 2004 to YTD 2011
PharmAthene, Inc., Deals Summary, 2004 to YTD 2011

List of Figures
PharmAthene, Inc. – Pipeline by Therapy Area and Indication, 2011
PharmAthene, Inc. – Pipeline by Stage of Development, 2011
PharmAthene, Inc. – Monotherapy Products in Pipeline, 2011
PharmAthene, Inc. – Combination Treatment Modalities in Pipeline, 2011
PharmAthene, Inc. – Pipeline By Therapeutic Class, 2011
PharmAthene, Inc. - Pipeline By Target, 2011
PharmAthene, Inc. – Pipeline By Route of Administration, 2011
PharmAthene, Inc. – Pipeline By Molecule Type, 2011

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Scientific Games Corporation - Company Analysis
• SunGard - Profile - US
• Ixia - Company Analysis
• eBay - Strong Execution
• Insight into Samsung Electronics' Notebook PC Business Model
• Amazon - Point of Realization in 2013?
• Analysis of Google Inc